Pharmacokinetics, in-vitro activity, therapeutic efficacy and clinical safety of aztreonam vs. cefotaxime in the treatment of complicated urinary tract infections.
暂无分享,去创建一个
K. Naber | H. Grobecker | F. Kees | G. Dette | H. Knothe
[1] M. Stern,et al. Oral bioavailability of the monobactam aztreonam (SQ 26,776) in healthy subjects , 1983, Antimicrobial Agents and Chemotherapy.
[2] E. Swabb,et al. Multiple-dose pharmacokinetics of the monobactam azthreonam (SQ 26,776) in healthy subjects , 1983, Antimicrobial Agents and Chemotherapy.
[3] R. Wise,et al. Pharmacokinetics and tissue penetration of azthreonam , 1982, Antimicrobial Agents and Chemotherapy.
[4] E. Swabb,et al. Single-dose pharmacokinetics of the monobactam azthreonam (SQ 26,776) in healthy subjects , 1982, Antimicrobial Agents and Chemotherapy.
[5] A. Heyrovský,et al. A new method for the determination of inulin in plasma and urine. , 1956, Clinica chimica acta; international journal of clinical chemistry.
[6] D. Adam,et al. Pharmakokinetik von Cefotaxim bei geriatrischen Patienten , 1980 .
[7] F. Knox,et al. The measurement of glomerular filtration rate in man with sodium iothalamate 131-I (Conray). , 1966, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.